HealthTech

Novartis returns for its anticoagulant in up to $3.1B b...

Nearly six years to the day after offloading its factor XI inhibitor to Blacksto...

Advancing Drug Development and Regulatory Compliance wi...

In recent years, regulatory bodies, such as the Food and Drug Administration (FD...

Intermountain Health Exec: Hub-and-Spoke Models Could S...

Dan Liljenquist, Intermountain Health’s chief strategy officer at Intermountain ...

Vertex operations chief Stuart Arbuckle to retire

Vertex chief operating officer Stuart Arbuckle plans to retire in July, the comp...

Accuryn Medical Appoints Todd Dunn as Chief Transformat...

What You Should Know:  – Accuryn Medical, a medical device company focused on ad...

HelloHero Secures Funding to Expand Access to Mental He...

What You Should Know:  – HelloHero, a provider of technology-enabled mental heal...

Epicore Biosystems Raises $26M to Advance Sweat-Sensing...

What You Should Know:  – Epicore Biosystems, an innovator in sweat-sensing weara...

GeneDx Launches on Epic Aura, Expanding Access to Genom...

What You Should Know:  – GeneDx, a leader in delivering improved health outcomes...

Philips, World Bank, and Ukraine Ministry of Health Par...

What You Should Know:  – Philips, a global leader in health technology, today an...

Lynx Secures $27M To Simplify Healthcare Payments

Lynx’s Series A round was led by Flare Capital Partners and included participati...

Judge halts some NIH cuts after 22 states sue

A federal court in Massachusetts temporarily blocked the Trump administration’s ...

Merck KGaA confirms interest in acquiring cancer biotec...

German pharma company Merck KGaA confirmed that it is in talks to acquire Spring...

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Eli Lilly is betting up to $630 million on an experimental MASH treatment from a...

States sue Trump administration over billions in NIH in...

Twenty-two state attorneys general sued the Trump administration on Monday in a ...

Hims’ Super Bowl ad has drawn criticism from lawmakers ...

Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl comme...

Pliant Therapeutics Presses Pause on Clinical Trial for...

A data safety monitoring board recommended pausing the Phase 2b test of Pliant’s...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.